Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 26Gastrointestinal 20Gynecologic 13Thoracic 10Head & Neck 9CNS 8Breast 6Lymphoid 5Other hematologic neoplasm 4Other solid neoplasm 3Dermatologic 3Sarcoma 2Other neoplasm 2Tumor-Agnostic 1Plasma cell 1NET 1Myeloid 1Endocrine 1Classical hematology 1

Conditions

Pancreatic Neuroendocrine Tumors (pNET) 1

Interventions

Everolimus 59lutetium Lu 177 dotatate 46Magnetic Resonance Spectroscopy 33pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 24lanreotide 23cabozantinib 22pasireotide 21gallium Ga 68 dotatate 21lenvatinib 20Etoposide 19Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18Sunitinib 17Bevacizumab 16trametinib 15dabrafenib 15Doxorubicin 143-Iodobenzylguanidine 14surufatinib 13Sorafenib 13Ipilimumab 13Thyrotropin Alfa 12Injections 12Positron Emission Tomography Computed Tomography 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Watchful Waiting × Endocrine × Clear all
NCT07591493 2026-05-15

ADJUPANET

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Not yet recruiting
300 enrolled
EndocrineGastrointestinalNET

Pancreatic Neuroendocrine Tumors (pNET)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡